Bortezomib
Active ingredient: Bortezomib
In short: Bortezomib Injection is indicated for the treatment of adult patients with multiple myeloma. Bortezomib Injection is indicated for the treatment of adult patients with mantle cell lymphoma.
What is Bortezomib used for?
Bortezomib Injection is indicated for the treatment of adult patients with multiple myeloma.
Bortezomib Injection is indicated for the treatment of adult patients with mantle cell lymphoma.
Bortezomib dosage
Bortezomib Injection is for intravenous or subcutaneous use only. Do not administer Bortezomib Injection by any other route.
Because each route of administration has a different final concentration, use caution when calculating the volume to be administered.
The recommended starting dose of Bortezomib Injection is 1.3 mg/m2. Bortezomib Injection is administered intravenously at a concentration of 1 mg/mL, or subcutaneously at a concentration of 2.5 mg/mL .
Bortezomib retreatment may be considered for patients with multiple myeloma who had previously responded to treatment with bortezomib and who have relapsed at least six months after completing prior bortezomib treatment. Treatment may be started at the last tolerated dose
.
When administered intravenously, administer Bortezomib Injection as a 3 to 5 second bolus intravenous injection.
Bortezomib Injection is administered in combination with oral melphalan and oral prednisone for 9, six week treatment cycles as shown in Table 1. In Cycles 1 to 4, Bortezomib Injection is administered twice weekly (Days 1, 4, 8, 11, 22, 25, 29 and 32). In Cycles 5 to 9, Bortezomib Injection is administered once weekly (Days 1, 8, 22 and 29). At least 72 hours should elapse between consecutive doses of Bortezomib Injection.
Twice Weekly Bortezomib Injection (Cycles 1 to 4)
Week | 1 | 2 | 3 | 4 | 5 | 6
Bortezomib Injection (1.3 mg/m2) | Day 1 | -- | -- | Day 4 | Day 8 | Day 11 | rest period | Day 22 | Day 25 | Day 29 | Day 32 | rest period
Melphalan (9 mg/m2) Prednisone (60 mg/m2) | Day 1 | Day 2 | Day 3 | Day 4 | -- | -- | rest period | -- | -- | -- | -- | rest period
Once Weekly Bortezomib Injection (Cycles 5 to 9 when used in combination with Melphalan and Prednisone)
Week | 1 | 2 | 3 | 4 | 5 | 6
Bortezomib Injection (1.3 mg/m2) | Day 1 | -- | -- | Day 8 | rest period | Day 22 | Day 29 | rest period
Melphalan (9 mg/m2) Prednisone (60 mg/m2) | Day 1 | Day 2 | Day 3 | Day 4 | -- | -- | rest period | -- | -- | -- | -- | rest period
Prior to initiating any cycle of therapy with Bortezomib Injection in combination with melphalan and prednisone:
Platelet count should be at least 70 x 109/L and the absolute neutrophil count (ANC) should be at least 1x 109/L
Non-hematological toxicities should have resolved to Grade 1 or baseline
Toxicity | Dose Modification or Delay
Hematological toxicity during a cycle: If prolonged Grade 4 neutropenia or thrombocytopenia, or thrombocytopenia with bleeding is observed in the previous cycle | Consider reduction of the melphalan dose by 25% in the next cycle
If platelet count is not above 30 × 109/L or ANC is not above 0.75 x 109/L on a Bortezomib Injection dosing day (other than Day 1) | Withhold Bortezomib Injection dose
If several Bortezomib Injection doses in consecutive cycles are …
How to take Bortezomib — instructions & advice from the label
Discuss the following with patients prior to treatment with Bortezomib Injection:
Peripheral Neuropathy
Advise patients to report the development or worsening of sensory and motor peripheral neuropathy to their healthcare provider .
Hypotension
Advise patients to drink adequate fluids to avoid dehydration and to report symptoms of hypotension to their healthcare provider .
Instruct patients to seek medical advice if they experience symptoms of dizziness, light headedness or fainting spells, or muscle cramps.
Cardiac Toxicity
Advise patients to report signs or symptoms of heart failure to their healthcare provider .
Pulmonary Toxicity
Advise patients to report symptoms of ARDS, pulmonary hypertension, pneumonitis, and pneumonia immediately to their healthcare provider .
Posterior Reversible Encephalopathy Syndrome (PRES)
Advise patients to seek immediate medical attention for signs or symptoms of PRES .
Gastrointestinal Toxicity
Advise patients to report symptoms of gastrointestinal toxicity to their healthcare provider and to drink adequate fluids to avoid dehydration. …
Warnings & precautions
Do not take this medicine if: Bortezomib Injection is contraindicated in patients with hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol. Reactions have included anaphylactic reactions .
Bortezomib Injection is contraindicated for intrathecal administration. Fatal events have occurred with intrathecal administration of bortezomib.
Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory; however, cases of severe sensory and motor peripheral neuropathy have been reported. Patients with pre-existing symptoms (numbness, pain or a burning feeling in the feet or hands) and/or signs of peripheral neuropathy may experience worsening peripheral neuropathy (including ≥Grade 3) during treatment with bortezomib. Patients should be monitored for symptoms of neuropathy, such as a burning sensation, hyperesthesia, hypoesthesia, paresthesia, discomfort, neuropathic pain or weakness. In the Phase 3 relapsed multiple myeloma trial comparing bortezomib subcutaneous vs intravenous, the incidence of Grade ≥2 peripheral neuropathy was 24% for subcutaneous and 39% for intravenous. Grade ≥3 peripheral neuropathy occurred in 6% of patients in the subcutaneous treatment group, compared with 15% in the intravenous treatment group . Starting bortezomib subcutaneously may be considered for patients with pre-existing or at high risk of peripheral neuropathy.
Patients experiencing new or worsening peripheral neuropathy during bortezomib therapy may require a decrease in the dose and/or a less dose-intense schedule . In the bortezomib vs dexamethasone Phase 3 relapsed multiple myeloma study, improvement in or resolution of peripheral neuropathy was reported in 48% of patients with ≥Grade 2 peripheral neuropathy following dose adjustment or interruption. …
Bortezomib side effects
The following clinically significant adverse reactions are also discussed in other sections of the labeling:
Peripheral Neuropathy
Hypotension
Cardiac Toxicity
Pulmonary Toxicity
Posterior Reversible Encephalopathy Syndrome (PRES)
Gastrointestinal Toxicity
Thrombocytopenia/Neutropenia
Tumor Lysis Syndrome
Hepatic Toxicity
Thrombotic Microangiopathy
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Summary of Clinical Trial in Patients with Previously Untreated Multiple Myeloma
Table 9 describes safety data from 340 patients with previously untreated multiple myeloma who received bortezomib (1.3 mg/m2) administered intravenously in combination with melphalan (9 mg/m2) and prednisone (60 mg/m2) in a prospective randomized study.
The safety profile of bortezomib in combination with melphalan/prednisone is consistent with the known safety profiles of both bortezomib and melphalan/prednisone. …
Drug interactions
Strong CYP3A4 Inducers
Coadministration with a strong CYP3A4 inducer decreases the exposure of bortezomib which may decrease bortezomib efficacy. Avoid coadministration with strong CYP3A4 inducers.
Strong CYP3A4 Inhibitors
Coadministration with a strong CYP3A4 inhibitor increases the exposure of bortezomib which may increase the risk of bortezomib toxicities. Monitor patients for signs of bortezomib toxicity and consider a bortezomib dose reduction if bortezomib must be given in combination with strong CYP3A4 inhibitors.
No clinically significant drug interactions have been observed when bortezomib was coadministered with dexamethasone, omeprazole, or melphalan in combination with prednisone .
About this medicine
Bortezomib Injection, a proteasome inhibitor, is an antineoplastic agent available for intravenous or subcutaneous injection. The chemical name for bortezomib {(1R)-3-Methyl-1-[(2S)-3-phenyl-2-(pyrazin-2-carboxamido)propanamido]butyl}boronic acid.
The structural formula is as follows:
The molecular formula of bortezomib is C19H25BN4O4; it has a molecular weight of 384.24. Bortezomib is freely soluble in methanol, ethanol and dimethyl sulfoxide, practically insoluble in toluene, pH range of 4 to 6.5.
Bortezomib Injection is available as a single-dose vial containing 3.5 mg of bortezomib as a sterile solution. Each 1 mL of solution contains 2.5 mg bortezomib, 25 mg mannitol, sodium chloride for isotonicity and water for injection.
How it works: Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 61539d49-dc21-4576-8813-4bc8abf3868c. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate